Clinical Efficacy of Two Treatment Regimens in the Treatment of Cough Variant Asthma and its Effects on Related Indicators

ZHANG Jin; LYU Conggai; GAO Naifen; ZHAO Lei

doi:10.14009/j.issn.1672-2124.2020.05.015

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Two Treatment Regimens in the Treatment of Cough Variant Asthma and its Effects on Related Indicators

更新时间：2022-10-08

- Clinical Efficacy of Two Treatment Regimens in the Treatment of Cough Variant Asthma and its Effects on Related Indicators
- Vol. 20, Issue 5, Pages: 567-570(2020)
- 作者机构：
  
  1. 石家庄市第二医院呼吸内科
  2. 石家庄市第二医院全科医学科
  3. 石家庄市第五医院内二科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.05.015
  CLC： R562.25
- Published：2020，
扫描看全文
[1]张瑾,吕从改,高耐芬,赵磊.两种方案治疗成人咳嗽变异性哮喘的临床疗效及对患者相关指标水平的影响[J].中国医院用药评价与分析,2020,20(05):567-570+575.

ZHANG Jin, LYU Conggai, GAO Naifen, et al. Clinical Efficacy of Two Treatment Regimens in the Treatment of Cough Variant Asthma and its Effects on Related Indicators. [J]. 20(5):567-570(2020)
[1]张瑾,吕从改,高耐芬,赵磊.两种方案治疗成人咳嗽变异性哮喘的临床疗效及对患者相关指标水平的影响[J].中国医院用药评价与分析,2020,20(05):567-570+575. DOI： 10.14009/j.issn.1672-2124.2020.05.015.

ZHANG Jin, LYU Conggai, GAO Naifen, et al. Clinical Efficacy of Two Treatment Regimens in the Treatment of Cough Variant Asthma and its Effects on Related Indicators. [J]. 20(5):567-570(2020) DOI： 10.14009/j.issn.1672-2124.2020.05.015.

摘要

目的:探讨沙美特罗替卡松与布地奈德分别联合孟鲁司特钠治疗成人咳嗽变异性哮喘（cough variant asthma

CVA）的疗效及对患者相关指标水平的影响。方法:选取2018年石家庄市第二医院和石家庄市第五医院收治的CVA患者90例

根据随机数字表法分为沙美特罗替卡松组、布地奈德组及对照组

每组30例。沙美特罗替卡松组患者采用沙美特罗替卡松+孟鲁司特钠治疗

布地奈德组患者采用布地奈德+孟鲁司特钠治疗

对照组患者单用布地奈德

三组患者均治疗3个月。观察三组患者的临床疗效、咳嗽症状积分

治疗前后血清白细胞介素2（IL-2）、白细胞介素4（IL-4）、肿瘤坏死因子α（TNF-α）、免疫球蛋白E（Ig E）、淀粉样蛋白A（SAA）、转化生长因子β1（TGF-β1）水平及肺功能指标[第1 s用力呼气容积（FEV

）、最大呼气流量（PEF）及FEV

占用力肺活量百分比（FEV

/FVC）]水平

比较三组患者不良反应发生情况的差异。结果:沙美特罗替卡松组、布地奈德组患者的总有效率分别为96.67%（29/30）、90.00%（27/30）

均明显高于对照组的73.33%（22/30）

差异有统计学意义（P

0.05）。治疗后1周

沙美特罗替卡松组、布地奈德组患者日间咳嗽症状积分和夜间咳嗽症状积分均明显低于对照组

差异有统计学意义（P

0.05）;治疗后2周

三组患者评分日间咳嗽症状积分和夜间咳嗽症状积分的差异均无统计学意义（P

0.05）。治疗后

三组患者IL-4、TNF-α、Ig E、SAA及TGF-β1水平明显低于治疗前

IL-2水平明显高于治疗前

差异均有统计学意义（P

0.05）;治疗后

沙美特罗替卡松组、布地奈德组患者IL-4、TNF-α、Ig E、SAA及TGF-β1水平明显低于对照组

IL-2水平明显高于对照组

差异均有统计学意义（P

0.05）。治疗后

三组患者FEV

、PEF及FEV

/FVC水平明显高于治疗前

且沙美特罗替卡松组、布地奈德组患者明显高于对照组

差异均有统计学意义（P

0.05）。沙美特罗替卡松组的血清IL-4、IL-2、TNF-α、Ig E、SAA及TGF-β1水平和肺功能指标水平改善情况优于布地奈德组

但差异均无统计学意义（P

0.05）。三组患者不良反应发生率的差异无统计学意义（χ

=2.069

P=0.355）。结论:CVA患者采用沙美特罗替卡松联合孟鲁司特钠和布地奈德联合孟鲁司特钠治疗

均能缓解机体炎症

有效改善肺功能

提高临床疗效。

Abstract

OBJECTIVE:To probe into the clinical efficacy of salmeterol and budesonide respectively combined with montelukast sodium in the treatment of cough variant asthma（CVA）and its effects on related indicators.METHODS:A total of 90 patients with CVA admitted into the Second Hospital of Shijiazhuang and the Fifth Hospital of Shijiazhuang in 2018 were extracted to be divided into the salmeterol group

the budesonide group and the control group via the random number table

with 30 cases in each group.Patients in the salmeterol group were treated with salmeterol and montelukast sodiumt

the budesonide group was given budesonide and montelukast sodium

and the control group received budesonide alone.All patients were treated for 3 months.The clinical efficacy

cough symptom scores

serum levels of interleukin-2（IL-2）

interleukin-4（IL-4）

tumor necrosis factor-α（TNF-α）

immunoglobulin E（IgE）

serum amyloid A（SAA）

transforming growth factor-β1（TGF-β1）and pulmonary function indicators[forced expiratory volume（FEV

）

maximum expiratory flow（PEF）and FEV

/forced vita capacity（FVC）at the end of the 1st second]of three groups were observed

differences of incidence of adverse drug reactions were compared.RESULTS:The total effective rates of the salmeterol group and the budesonide group were96.67%（29/30）and 90.00%（27/30）

significantly higher than 73.33%（22/30）of the control group

the difference was statistically significant（P

0.05）.After treatment of one week

the scores of daytime cough symptom and nighttime cough symptom in the salmeterol group and budesonide group were significantly lower than those in the control group

the difference was statistically significant（P

0.05）.After treatment of two weeks

there was no significant difference in scores of daytime cough symptom and nighttime cough symptom among three groups（P

0.05）.After treatment

the levels of IL-4

TNF-α

IgE

SAA and TGF-β1 in three groups were significantly lower than those before treatment

and the levels of IL-2 were significantly higher than those before treatment

with statistically significant differences（P

0.05）.After treatment

the levels of IL-4

TNF-α

IgE

SAA and TGF-β1 in the salmeterol group and the budesonide group were significantly lower than those in the control group

and the levels of IL-2 were significantly higher than those in the control group

with statistically significant differences（P

0.05）After treatment

the levels of FEV

PEF and FEV

/FVC in three groups were significantly higher than those before treatment

the salmeterol group and the budesonide group were significantly higher than the control group

with statistically significant differences（P

0.05）.The improvement of serum levels of IL-4

IL-2

TNF-α

IgE

SAA and TGF-β1 and pulmonary function indicators in the salmeterol group was better than that in the budesonide group

ye the difference was not statistically significant（P

0.05）.There was no statistically significant difference in the incidence of adverse drug reactions among three groups（χ

=2.069

P=0.355）.CONCLUSIONS:Salmetero combined with montelukast sodium and budesonide combined with montelukast in the treatment of patients with CVA can alleviate the inflammation of the patients

thereby effectively improving the pulmonary function and improving the clinical efficacy.

关键词

咳嗽变异性哮喘沙美特罗替卡松孟鲁司特钠肺功能炎症因子

Keywords

Cough variant asthmaSalmeterolMontelukast sodiumPulmonary functionInflammatory factors

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Reduced Glutathione Infusion on Inflammatory Response in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Effects of Budesonide for Inhalation on Ventilator Weaning Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma

Efficacy of Xuanfei Tongluo Formula in the Treatment of Children with Mycoplasma Pneumoniae Pneumonia and Its Effects on Inflammatory Factors, sIgA, hBD2 and CAL

Effects of BiPAP Combined with Salmeterol and Ficasone Inhalation Aerosol on Immune Globulin, Pulmonary Function and Inflammatory Factors in Patients with Chronic Obstructive Pulmonary Disease Complicated with Respiratory Failure

Related Author

CHEN Chen

WANG Yang

ZHANG Xiangru

ZHU Bai

SUN Zhongmin

CHEN Tianjun

LYU Yuan

PEI Kai

Related Institution

Dept.of Cardiology, the First Affiliated Hospital of Xi’an Jiaotong University

Dept.of Pharmacy, the First Affiliated Hospital of Xi’an Jiaotong University

Dept.of Respiratory,the First Affiliated Hospital,Xi’an Jiaotong University

Dept.of Pharmacy,the First affiliated Hospital,Xi’an Jiaotong University

Dept.of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Guangxi University of Chinese Medicine

⁰